FDA Approves New IV Tx for Pompe Disease – Nexviazyme
Last week the FDA approved a new, INFUSED enzyme replacement therapy, Nexviazyme (avalglucosidase alfa-ngpt) from Genzyme, indicated to treat patients 1 year of age and
August 10, 2021
Last week the FDA approved a new, INFUSED enzyme replacement therapy, Nexviazyme (avalglucosidase alfa-ngpt) from Genzyme, indicated to treat patients 1 year of age and
It was way back in March of 2015 when the first biosimilar was approved. There was much consternation over the impact that biosimilars would have
The FDA recently approved a new therapy, Saphnelo (anifrolumab-fnia) from AstraZeneca, as a treatment for adults with systemic lupus erythematosus (SLE) who are receiving standard
The FDA recently approved a new ORAL therapy, Bylvay (odevixibat) from Albireo Pharma, with an indication for treating pruritus in all subtypes of progressive familial
One of my favorite topics…. Hospitals and health systems opening their own specialty pharmacies (HSSPs). We’ve written about this growing trend for several years, but
The FDA recently approved a new ORAL therapy, Rezurock (belumosudil) from Kadmon Pharmaceuticals, with an indication for adult and pediatric patients with chronic graft-versus-host disease
We’ve often written about the legal pitfalls that specialty pharmacies may encounter that end up costing them financially (HIPAA violations are top of mind). Today
Earlier this month the FDA approved a ‘new’ combination therapy, Darzalex Faspro (daratumumab and hyaluronidase-fihj), from Janssen Biotech. Darzalex was originally approved in 2015 with
It’s about time.It has been quite a while since we’ve heard about a specialty pharmacy acquisition. Over recent years there was a race to the
The public relations battle surrounding White Bagging is heating up.Who’s on each side?Depends on who you ask….!On one side, hospitals are claiming that their very
